As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
NanoViricides received National Ethics Committee approval in the DRC for a Phase II trial of NV-387 Oral Gummies to treat the Bundibugyo Ebolavirus. With the drug already on-site for a concurrent Mpox trial, the company is preparing to file regulatory submissions to ACOREP to begin the study amidst an outbreak that has infected 1,926 people. CEO Anil R.
Key figures
- Drug Name
- NV-387
- Phase Of Trial
- Phase II
- Deaths
- 702
- Confirmed cases
- 1926
- Projected cases high end
- 20000
- Projected deaths high end
- 4000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.